InMed Pharmaceuticals (INM) Gross Margin (2021 - 2025)
InMed Pharmaceuticals (INM) posted quarterly Gross Margin of 22.46% for Q4 2025, down 1900.0% year-over-year from 1.25% in Q4 2024, and down 37.6% quarter-over-quarter from 35.99% in Q3 2025.
InMed Pharmaceuticals (INM) Gross Margin (2021 - 2025) Analysis & Trends
InMed Pharmaceuticals' Gross Margin history runs 5 years deep, the most recent figure standing at 22.46% for Q4 2025.
- In Q4 2025, Gross Margin fell 1900.0% year-over-year to 22.46%; the TTM figure through Dec 2025 stood at 29.73% (down 566.0% YoY), while the FY2025 annual figure was 34.53%, up 1058.0% from the prior year.
- Gross Margin for Q4 2025 stood at 22.46%, down from 35.99% in the prior quarter.
- The five-year high for Gross Margin was 67.95% in Q2 2023, with the low at 153.07% in Q3 2022.
- The 5-year median for Gross Margin is 30.38% (2022), against an average of 21.7%.
- The sharpest annual moves came in 2023 and 2024: Gross Margin soared 15542 bps in 2023, then plunged 3163 bps in 2024.
- InMed Pharmaceuticals' Gross Margin stood at 42.08% in 2021, then sank by 34 bps to 27.92% in 2022, then decreased by 6 bps to 26.14% in 2023, then surged by 59 bps to 41.46% in 2024, then sank by 46 bps to 22.46% in 2025.
- Business Quant data shows INM's Gross Margin at 22.46% in Q4 2025, 35.99% in Q3 2025, and 44.2% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 51.98% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 42.63% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 66.66% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.30% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 38.77% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 97.58% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 58.33% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.36 Mn | 1.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.46% |
| Sep 30, 2025 | 35.99% |
| Jun 30, 2025 | 44.20% |
| Mar 31, 2025 | 13.92% |
| Dec 31, 2024 | 41.46% |
| Sep 30, 2024 | 39.02% |
| Jun 30, 2024 | 36.32% |
| Mar 31, 2024 | 24.69% |
| Dec 31, 2023 | 26.14% |
| Sep 30, 2023 | 2.36% |
| Jun 30, 2023 | 67.95% |
| Mar 31, 2023 | 18.62% |
| Dec 31, 2022 | 27.92% |
| Sep 30, 2022 | -153.07% |
| Jun 30, 2022 | 48.51% |
| Mar 31, 2022 | 30.38% |
| Dec 31, 2021 | 42.08% |